ALSO NOTED: Gene Logic takes second look at Merck KGaA drugs; Zars mounts IPO;

> A subsidiary of Germany-based Merck KGaA has inked a deal to help reposition and develop several of Gene Logic's potential drugs. The candidates had been subject of previous clinical trials that were discontinued "for reasons other than safety." Release

> Lobbyists for Herceptin coverage in New Zealand presented a 27,000-signature petition to Parliament in support of the drug. The activists want NZ drug authority PHARMAC to fund 12 months of Herceptin treatment, instead of the 9 weeks that's currently covered. Report

> AspenBio Pharma will step onto the NASDAQ exchange Tuesday. The company got approval to list its stock, using the symbol APPY. Report

> Zars Pharma, a maker of topical pain relievers, is mounting an initial public offering of 5 million shares in hopes of raising up to $78 million for clinical testing of new product candidates. Report

And Finally... A breakthrough study suggests Huntington's might be treated with existing drugs. Researchers at the University of Leeds say they've identified a protein that keeps 57 genes from working properly in Huntington's patients--and cancer drugs may help destroy that protein. Report